Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Clara Andradas is active.

Publication


Featured researches published by Clara Andradas.


Oncogene | 2011

The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK

Clara Andradas; María M. Caffarel; Eduardo Pérez-Gómez; María Salazar; Mar Lorente; Guillermo Velasco; Manuel Guzmán; Cristina Sánchez

GPR55 is an orphan G protein-coupled receptor that may be engaged by some lipid ligands such as lysophosphatidylinositol and cannabinoid-type compounds. Very little is known about its expression pattern and physio-pathological relevance, and its pharmacology and signaling are still rather controversial. Here we analyzed the expression and function of GPR55 in cancer cells. Our data show that GPR55 expression in human tumors from different origins correlates with their aggressiveness. Moreover, GPR55 promotes cancer cell proliferation, both in cell cultures and in xenografted mice, through the overactivation of the extracellular signal-regulated kinase cascade. These findings reveal the importance of GPR55 in human cancer, and suggest that it could constitute a new biomarker and therapeutic target in oncology.


Molecular Cancer | 2010

Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition

María M. Caffarel; Clara Andradas; Emilia Mira; Eduardo Pérez-Gómez; Camilla Cerutti; Gema Moreno-Bueno; Juana M. Flores; Isabel García-Real; José Palacios; Santos Mañes; Manuel Guzmán; Cristina Sánchez

BackgroundErbB2-positive breast cancer is characterized by highly aggressive phenotypes and reduced responsiveness to standard therapies. Although specific ErbB2-targeted therapies have been designed, only a small percentage of patients respond to these treatments and most of them eventually relapse. The existence of this population of particularly aggressive and non-responding or relapsing patients urges the search for novel therapies. The purpose of this study was to determine whether cannabinoids might constitute a new therapeutic tool for the treatment of ErbB2-positive breast tumors. We analyzed their antitumor potential in a well established and clinically relevant model of ErbB2-driven metastatic breast cancer: the MMTV-neu mouse. We also analyzed the expression of cannabinoid targets in a series of 87 human breast tumors.ResultsOur results show that both Δ9-tetrahydrocannabinol, the most abundant and potent cannabinoid in marijuana, and JWH-133, a non-psychotropic CB2 receptor-selective agonist, reduce tumor growth, tumor number, and the amount/severity of lung metastases in MMTV-neu mice. Histological analyses of the tumors revealed that cannabinoids inhibit cancer cell proliferation, induce cancer cell apoptosis, and impair tumor angiogenesis. Cannabinoid antitumoral action relies, at least partially, on the inhibition of the pro-tumorigenic Akt pathway. We also found that 91% of ErbB2-positive tumors express the non-psychotropic cannabinoid receptor CB2.ConclusionsTaken together, these results provide a strong preclinical evidence for the use of cannabinoid-based therapies for the management of ErbB2-positive breast cancer.


Molecular Endocrinology | 2011

Minireview: Recent Developments in the Physiology and Pathology of the Lysophosphatidylinositol-Sensitive Receptor GPR55

Christopher M. Henstridge; Nariman Balenga; Julia Kargl; Clara Andradas; Andrew J. Brown; Andrew J. Irving; Cristina Sánchez; Maria Waldhoer

Emerging data suggest that off-target cannabinoid effects may be mediated via novel seven-transmembrane spanning/G protein-coupled receptors. Due to its cannabinoid sensitivity, the G protein-coupled receptor 55 (GPR55) was recently proposed as a candidate; however, GPR55 is phylogenetically distinct from the traditional cannabinoid receptors, and the conflicting pharmacology, signaling, and functional data have prevented its classification as a novel cannabinoid receptor. Indeed, the most consistent and potent agonist to date is the noncannabinoid lysophospholipid, lysophosphatidylinositol. Here we present new human GPR55 mRNA expression data, providing supportive evidence of GPR55 expression in a vast array of tissues and cell types. Moreover, we summarize major recent developments in GPR55 research and aim to update the reader in the rapidly expanding fields of GPR55 pharmacology, physiology, and pathology.


Oncogene | 2013

The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas

Eduardo Pérez-Gómez; Clara Andradas; Juana M. Flores; Miguel Quintanilla; J M Paramio; Manuel Guzmán; Cristina Sánchez

G protein-coupled receptors (GPCRs) control crucial physiological processes and their dysfunction contributes to various human diseases, including cancer. The orphan GPCR GPR55 was identified and cloned more than a decade ago, but very little is known about its physio-pathological relevance. It has been recently shown that GPR55 controls the behavior of human cancer cell lines in culture and xenografts. However, the assessment of the actual role of this receptor in malignant transformation in vivo is hampered by the lack of studies on its functional impact in clinically-relevant models of cancer. Here we demonstrate that GPR55 drives mouse skin tumor development. Thus, GPR55-deficient mice were more resistant to DMBA/TPA-induced papilloma and carcinoma formation than their wild-type littermates. GPR55 exerted this pro-tumor effect primarily by conferring a proliferative advantage on cancer cells. In addition, GPR55 enhanced skin cancer cell anchorage-independent growth, invasiveness and tumorigenicity in vivo, suggesting that it promotes not only tumor development but also tumor aggressiveness. Finally, we observed that GPR55 is upregulated in human skin tumors and other human squamous cell carcinomas compared with the corresponding healthy tissues. Altogether, these findings reveal the pivotal importance of GPR55 in skin tumor development, and suggest that this receptor may be used as a new biomarker and therapeutic target in squamous cell carcinomas.


Cancer Treatment Reviews | 2012

Cannabinoids: a new hope for breast cancer therapy?

María M. Caffarel; Clara Andradas; Eduardo Pérez-Gómez; Manuel Guzmán; Cristina Sánchez

Breast cancer is a very common disease that affects approximately 1 in 10 women at some point in their lives. Importantly, breast cancer cannot be considered a single disease as it is characterized by distinct pathological and molecular subtypes that are treated with different therapies and have diverse clinical outcomes. Although some highly successful treatments have been developed, certain breast tumors are resistant to conventional therapies and a considerable number of them relapse. Therefore, new strategies are urgently needed, and the challenge for the future will most likely be the development of individualized therapies that specifically target each patients tumor. Experimental evidence accumulated during the last decade supports that cannabinoids, the active components of Cannabis sativa and their derivatives, possess anticancer activity. Thus, these compounds exert anti-proliferative, pro-apoptotic, anti-migratory and anti-invasive actions in a wide spectrum of cancer cells in culture. Moreover, tumor growth, angiogenesis and metastasis are hampered by cannabinoids in xenograft-based and genetically-engineered mouse models of cancer. This review summarizes our current knowledge on the anti-tumor potential of cannabinoids in breast cancer, which suggests that cannabinoid-based medicines may be useful for the treatment of most breast tumor subtypes.


Journal of Biological Chemistry | 2014

Targeting CB2-GPR55 Receptor Heteromers Modulates Cancer Cell Signaling

Estefanía Moreno; Clara Andradas; Mireia Medrano; María M. Caffarel; Eduardo Pérez-Gómez; Sandra Blasco-Benito; María Gómez-Cañas; M. Ruth Pazos; Andrew J. Irving; Carme Lluis; Enric I. Canela; Javier Fernández-Ruiz; Manuel Guzmán; Peter J. McCormick; Cristina Sánchez

Background: Cannabinoid receptor CB2 (CB2R) and GPR55 are overexpressed in cancer cells and control cell fate. Results: In cancer cells, CB2R and GPR55 form heteromers that impact the signaling of each protomer. Conclusion: CB2R-GPR55 heteromers drive biphasic signaling responses as opposed to the individual receptors via cross-antagonism. Significance: These heteromers may explain some of the biphasic effects of cannabinoids and, therefore, constitute potential new targets in oncology. The G protein-coupled receptors CB2 (CB2R) and GPR55 are overexpressed in cancer cells and human tumors. Because a modulation of GPR55 activity by cannabinoids has been suggested, we analyzed whether this receptor participates in cannabinoid effects on cancer cells. Here we show that CB2R and GPR55 form heteromers in cancer cells, that these structures possess unique signaling properties, and that modulation of these heteromers can modify the antitumoral activity of cannabinoids in vivo. These findings unveil the existence of previously unknown signaling platforms that help explain the complex behavior of cannabinoids and may constitute new targets for therapeutic intervention in oncology.


Journal of the National Cancer Institute | 2015

Role of Cannabinoid Receptor CB2 in HER2 Pro-oncogenic Signaling in Breast Cancer

Eduardo Pérez-Gómez; Clara Andradas; Sandra Blasco-Benito; María M. Caffarel; Elena García-Taboada; María Villa-Morales; Estefanía Moreno; Sigrid Hamann; Ester Martín-Villar; Juana M. Flores; Antonia Wenners; Ibrahim Alkatout; Wolfram Klapper; Christoph Röcken; Peter Bronsert; Elmar Stickeler; Annette Staebler; Maret Bauer; Norbert Arnold; Joaquim Soriano; Manuel Pérez-Martínez; Diego Megías; Gema Moreno-Bueno; Silvia Ortega-Gutiérrez; Marta Artola; Henar Vázquez-Villa; Miguel Quintanilla; José Fernández-Piqueras; Enric I. Canela; Peter J. McCormick

BACKGROUND Pharmacological activation of cannabinoid receptors elicits antitumoral responses in different cancer models. However, the biological role of these receptors in tumor physio-pathology is still unknown. METHODS We analyzed CB2 cannabinoid receptor protein expression in two series of 166 and 483 breast tumor samples operated in the University Hospitals of Kiel, Tübingen, and Freiburg between 1997 and 2010 and CB2 mRNA expression in previously published DNA microarray datasets. The role of CB2 in oncogenesis was studied by generating a mouse line that expresses the human V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) rat ortholog (neu) and lacks CB2 and by a variety of biochemical and cell biology approaches in human breast cancer cells in culture and in vivo, upon modulation of CB2 expression by si/shRNAs and overexpression plasmids. CB2-HER2 molecular interaction was studied by colocalization, coimmunoprecipitation, and proximity ligation assays. Statistical tests were two-sided. RESULTS We show an association between elevated CB2 expression in HER2+ breast tumors and poor patient prognosis (decreased overall survival, hazard ratio [HR] = 0.29, 95% confidence interval [CI] = 0.09 to 0.71, P = .009) and higher probability to suffer local recurrence (HR = 0.09, 95% CI = 0.049 to 0.54, P = .003) and to develop distant metastases (HR = 0.33, 95% CI = 0.13 to 0.75, P = .009). We also demonstrate that genetic inactivation of CB2 impairs tumor generation and progression in MMTV-neu mice. Moreover, we show that HER2 upregulates CB2 expression by activating the transcription factor ELK1 via the ERK cascade and that an increased CB2 expression activates the HER2 pro-oncogenic signaling at the level of the tyrosine kinase c-SRC. Finally, we show HER2 and CB2 form heteromers in cancer cells. CONCLUSIONS Our findings reveal an unprecedented role of CB2 as a pivotal regulator of HER2 pro-oncogenic signaling in breast cancer, and they suggest that CB2 may be a biomarker with prognostic value in these tumors.


Journal of Medicinal Chemistry | 2015

Selective, nontoxic CB2 cannabinoid o-quinone with in vivo activity against triple-negative breast cancer

Paula Morales; Sandra Blasco-Benito; Clara Andradas; María Gómez-Cañas; Juana M. Flores; Pilar Goya; Javier Fernández-Ruiz; Cristina Sánchez; Nadine Jagerovic

Triple-negative breast cancer (TNBC) represents a subtype of breast cancer characterized by high aggressiveness. There is no current targeted therapy for these patients whose prognosis, as a group, is very poor. Here, we report the synthesis and evaluation of a potent antitumor agent in vivo for this type of breast cancer designed as a combination of quinone/cannabinoid pharmacophores. This new compound (10) has been selected from a series of chromenopyrazolediones with full selectivity for the nonpsychotropic CB2 cannabinoid receptor and with efficacy in inducing death of human TNBC cell lines. The dual concept quinone/cannabinoid was supported by the fact that compound 10 exerts antitumor effect by inducing cell apoptosis through activation of CB2 receptors and through oxidative stress. Notably, it did not show either cytotoxicity on noncancerous human mammary epithelial cells nor toxic effects in vivo, suggesting that it may be a new therapeutic tool for the management of TNBC.


Oncotarget | 2016

Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer.

Clara Andradas; Sandra Blasco-Benito; Sonia Castillo-Lluva; Patricia Dillenburg-Pilla; R. Díez-Alarcia; Alba Juanes-García; Elena García-Taboada; Rodrigo Hernando-Llorente; Joaquim Soriano; Sigrid Hamann; Antonia Wenners; Ibrahim Alkatout; Wolfram Klapper; Christoph Röcken; Maret Bauer; Norbert Arnold; Miguel Quintanilla; Diego Megías; Miguel Vicente-Manzanares; Leyre Urigüen; J. Silvio Gutkind; Manuel Guzmán; Eduardo Pérez-Gómez; Cristina Sánchez

The orphan G protein-coupled receptor GPR55 has been directly or indirectly related to basic alterations that drive malignant growth: uncontrolled cancer cell proliferation, sustained angiogenesis, and cancer cell adhesion and migration. However, little is known about the involvement of this receptor in metastasis. Here, we show that elevated GPR55 expression in human tumors is associated with the aggressive basal/triple-negative breast cancer population, higher probability to develop metastases, and therefore poor patient prognosis. Activation of GPR55 by its proposed endogenous ligand lysophosphatidylinositol confers pro-invasive features on breast cancer cells both in vitro and in vivo. Specifically, this effect is elicited by coupling to Gq/11 heterotrimeric proteins and the subsequent activation, through ERK, of the transcription factor ETV4/PEA3. Together, these data show that GPR55 promotes breast cancer metastasis, and supports the notion that this orphan receptor may constitute a new therapeutic target and potential biomarker in the highly aggressive triple-negative subtype.


Journal of Medicinal Chemistry | 2015

New Inhibitors of Angiogenesis with Antitumor Activity in Vivo

Nagore I. Marín-Ramos; Dulce Alonso; Silvia Ortega-Gutiérrez; Francisco J. Ortega-Nogales; Moisés Balabasquer; Henar Vázquez-Villa; Clara Andradas; Sandra Blasco-Benito; Eduardo Pérez-Gómez; Ángeles Canales; Jesús Jiménez-Barbero; Ana Marquina; Jaime Moscoso del Prado; Cristina Sánchez; Mar Martín-Fontecha; María L. López-Rodríguez

Angiogenesis is a requirement for the sustained growth and proliferation of solid tumors, and the development of new compounds that induce a sustained inhibition of the proangiogenic signaling generated by tumor hypoxia still remains as an important unmet need. In this work, we describe a new antiangiogenic compound (22) that inhibits proangiogenic signaling under hypoxic conditions in breast cancer cells. Compound 22 blocks the MAPK pathway, impairs cellular migration under hypoxic conditions, and regulates a set of genes related to angiogenesis. These responses are mediated by HIF-1α, since the effects of compound 22 mostly disappear when its expression is knocked-down. Furthermore, administration of compound 22 in a xenograft model of breast cancer produced tumor growth reductions ranging from 46 to 55% in 38% of the treated animals without causing any toxic side effects. Importantly, in the responding tumors, a significant reduction in the number of blood vessels was observed, further supporting the mechanism of action of the compound. These findings provide a rationale for the development of new antiangiogenic compounds that could eventually lead to new drugs suitable for the treatment of some types of tumors either alone or in combination with other agents.

Collaboration


Dive into the Clara Andradas's collaboration.

Top Co-Authors

Avatar

Cristina Sánchez

Complutense University of Madrid

View shared research outputs
Top Co-Authors

Avatar

Eduardo Pérez-Gómez

Complutense University of Madrid

View shared research outputs
Top Co-Authors

Avatar

Manuel Guzmán

Complutense University of Madrid

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sandra Blasco-Benito

Complutense University of Madrid

View shared research outputs
Top Co-Authors

Avatar

Juana M. Flores

Complutense University of Madrid

View shared research outputs
Top Co-Authors

Avatar

Elena García-Taboada

Complutense University of Madrid

View shared research outputs
Top Co-Authors

Avatar

Miguel Quintanilla

Spanish National Research Council

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge